Published in final edited form as:

Angew Chem Int Ed Engl. 2014 August 04; 53(32): 8467–8470. doi:10.1002/anie.201404570.

Rhodium Catalyzed Asymmetric Hydrogenation of Unprotected N-H Imines Assisted by Thiourea**

Qingyang Zhao,

Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Lanzhou University, Lanzhou 730000, China

Department of Chemistry & Chemical Biology, Department of Medicinal Chemistry, Rutgers, The State University of New Jersey, 610 Taylor Road, Piscataway, New Jersey 08854, USA

Jialin Wen,

Department of Chemistry & Chemical Biology, Department of Medicinal Chemistry, Rutgers, The State University of New Jersey, 610 Taylor Road, Piscataway, New Jersey 08854, USA

Renchang Tan,

Department of Chemistry & Chemical Biology, Department of Medicinal Chemistry, Rutgers, The State University of New Jersey, 610 Taylor Road, Piscataway, New Jersey 08854, USA

Kexuan Huang,

Department of Chemistry & Chemical Biology, Department of Medicinal Chemistry, Rutgers, The State University of New Jersey, 610 Taylor Road, Piscataway, New Jersey 08854, USA

Pedro Metola,

Department of Chemistry, The University of Texas at Austin 1 University Station A5300, Austin, TX 78712-0165

Rui Wang,

Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Lanzhou University, Lanzhou 730000, China

Eric V. Anslyn, and

Department of Chemistry, The University of Texas at Austin 1 University Station A5300, Austin, TX 78712-0165

Xumu Zhang

Department of Chemistry & Chemical Biology, Department of Medicinal Chemistry, Rutgers, The State University of New Jersey, 610 Taylor Road, Piscataway, New Jersey 08854, USA

Abstract

Asymmetric hydrogenation of unprotected N-H imines catalyzed by Rh/bisphosphine-thiourea provided chiral amines with up to 97% yield and 95% ee. ¹H NMR studies, coupled with control experiments, implied that catalytic chloride-bound intermediates were involved in the mechanism

**This work was supported by the National Science Foundation (NSF CHE 0956784), the China Scholarship Council, the National S&T Major Project of China (2012ZX09504001-003) and the National Institutes of Health (NIH R01GM077437).

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201xxxxxx>.

via the dual hydrogen-bonding interaction. Deuteration experiments proved that the hydrogenation proceeded through a pathway consistent with the imine.

Graphical abstract

Bisphosphine-thiourea was successfully used in the Rh catalyzed asymmetric hydrogenation of unprotected iminium salts (up to 97% yield and 95% *ee*). Even if 0.2 mol % catalyst was used, 95% conversion and 94% *ee* was obtained. The control experiments and ^1H NMR studies implied that the anion binding between the thiourea and chloride ions was involved in the mechanism. Deuteration experiments proved that the hydrogenation proceeded through a pathway consistent with the imine.

Keywords

asymmetric catalysis; hydrogenation; ion pairs; ketimine; rhodium

Chiral amines are powerful pharmacophores of biologically active molecules for pharmaceuticals and agrochemicals, such as the elastase inhibitor DMP 777, calcimimetic agent Sensipar (Cinacalcet) and type II calcimimetics NPS *R*-568. (Figure 1).^[1] As one of the most efficient synthetic approaches, metal-catalyzed asymmetric hydrogenation deserves special attention. Many successful catalytic systems have been developed, including asymmetric reductive amination and asymmetric hydrogenation of enamines and imines.^[1–7] However, owing to the complex interactions between catalysts and substrates/products, the imine-enamine tautomerization and the *E/Z* interconversion of imines, asymmetric hydrogenation of enamines and imines is still a largely underdeveloped area in contrast to the advances of olefins and ketones.^[1b] Unprotected *N*-H imines and enamines are attractive but challenging substrates.^[3–5] Asymmetric hydrogenation of them eliminates the use of *N*-protecting groups and has broad potential applications in industry. To date, although there are several successful examples of unprotected enamines in academic research and industrial utilization,^[3] the unprotected imines are rarely studied.^[4,5] Our group reported the first example of iminium salts^[5] involved in the substrate activation strategy^[1e,3–7] with well-studied Ir-based catalysts. We aimed to develop a novel and efficient Rh-based catalytic system for this transformation.

Thiourea has been widely used as a hydrogen-bond donor in organocatalysis.^[8] Most research focuses on the direct activation of neutral substrates by hydrogen bonding while recent studies take advantage of the anion binding of ion-pairing intermediates.^[9] Inspired by the strategies developed in organocatalysis^[10–12] and our previous research on the Rh/bisphosphine catalyzed asymmetric hydrogenation of nitroalkenes assisted by thiourea,^[13] we sought to extend anion-binding catalysis to the transition metal-catalyzed asymmetric

hydrogenation. We envisioned that thiourea could interact with a counterion in the catalytic pathway (Figure 2).

Herein, we describe the first example of Rh/bisphosphine catalyzed asymmetric hydrogenation of unprotected *N*-H imines assisted by thiourea with up to 97% yield and 95% *ee*.

As we reported previously,^[13] the catalytic system was solvent dependent and poor results were given using Ir, Pd and Ru.^[14] In addition, pressures, temperatures and additives were examined to study the turnover number (TON) limit of this transformation.^[14] 99% conversion and 94% *ee* was observed with 1 mol % catalyst at 25 °C under 10 atm H₂ (Scheme 1). Even if 0.2 mol % catalyst was used, 95% conversion and 94% *ee* was obtained. This system provided remarkably higher TON than our previous Ir-f-Binaphane catalytic system (5 mol % catalyst).^[5]

Under the optimized conditions, a variety of *N*-H imines were tested (Scheme 2). Most substrates with *meta* and *para* substitutions on the phenyl ring afforded high yields and enantioselectivities (92-97% yield and 90-95% *ee*). However, the chloro group and methoxy group resulted in an obvious decrease of the yields. The *ortho*-methoxy group on the phenyl ring resulted in 34% yield and 84% *ee* (**2i**). 1-naphthyl and 2-naphthyl amines were obtained with 95% *ee* and 92% *ee* respectively (**2j** and **2k**). Changing the R² group had a significant effect on the outcome. When R² was ethyl group, both lower conversion and enantioselectivity were observed (**2l**). As the R² was changed to bulkier butyl group, further loss of conversion and enantioselectivity was observed (**2m**). The catalytic system displayed low activity and enantioselectivity for dialkyl ketimine (**2n**) and diaryl ketimine.^[15] Otherwise, 2-methyl quinolinium chloride was hydrogenated in 97% yield with 82% *ee* at 25 °C under 5 atm H₂ with 1 mol % catalyst (**2o**).

To obtain insight into this catalytic system, a series of chiral ligands were prepared and control experiments were undertaken (Table 1). Consistent with our recent report,^[13] the Rh-bisphosphine complex without (thio)urea motif (**L1**) showed very low activity and enantioselectivity (Table 1, entry 1). Urea **L2** provided 22% conversion and 66% *ee* in sharp contrast with the thiourea **L6** (Table 1, entry 2 vs. 6). The CF₃ group on the 3,5-bis(trifluoromethyl)phenyl moiety remained important in the catalytic system (Table 1, entries 3-5).^[16] The *N*-methylation of **L6** led to a dramatic decrease of the conversion and enantioselectivity (Table 1, entry 7), which suggested that the NH was involved in the activation of iminium salts and the stereoselectivity of hydrogenation. Furthermore, the low conversion and enantioselectivity obtained with monodentate phosphorus ligands implied that the bisphosphine moiety was essential (Table 1, entry 9). Importantly, neither the combination of the chiral phosphine with the thiourea, nor the combination of the chiral thiourea with the simple phosphine improved this reaction (Table 1, entry 1 vs. 11, entry 8 vs. 10), which pointed to the importance of the covalent linker for high activity and enantioselectivity.

Different counterions and additives were also investigated (Table 2). When the chloride counterion in **1a** was replaced with trifluoromethanesulfonate, only 20% conversion and

53% *ee* was observed (Table 2, entry 1). Interestingly, the addition of chloride counterion from LiCl and tetrabutylammonium chloride (TBAC) increased the conversions and enantioselectivities (Table 2, entries 2 and 3). However, the addition of bromide from tetrabutylammonium bromide (TBAB) and iodide counterions from tetrabutylammonium iodide (TBAI) decreased the conversions and enantioselectivities (Table 2, entries 4-6). This phenomenon implied that the chloride ion played a crucial role in the catalytic system.

Further information about the reaction was provided by ^1H NMR studies of mixtures generated from ligands and TBAC (Figure 3). The addition of varying amounts of TBAC to **L6** in CDCl_3 resulted in downfield shifts of the NH proton signals. However, no change was observed for the NH proton signal of **L7**. Analogous experiments employing a series of different ligands gave similar results.^[14] This finding was consistent with a dual hydrogen-bonding interaction between the catalyst's thiourea and chloride ions.^[10c,10f,12b] This observation, coupled with the fact that optimal yields and *ee* values involve chloride ions, led us to propose that catalytic chloride-bound intermediates are involved in the mechanism via the dual hydrogen-bonding interaction (Figure 2).

To gain further insight into this transformation, the asymmetric hydrogenation was performed under D_2 . ^1H NMR analysis of the crude product showed that **2a** had incorporated deuterium in the α -position (Scheme 3), suggesting that the hydrogenation proceeded through a pathway consistent with the imine.^[3c,5a,14]

With the ultimate goal being the fast screening of reaction conditions in the future, we initiated collaborative work with the Anslyn group and verified their method to measure *ee* values of chiral amines based on circular dichroism (CD) spectroscopy.^[17] Although the accuracy is not ideal (an average absolute error of 9%),^[14] it is much faster and being transitioned to aid in our research.

In conclusion, we report the first Rh/bisphosphine-thiourea catalyzed asymmetric hydrogenation of unprotected *N*-H imines. The chiral amines were obtained in high yields and enantioselectivities. Based on the control experiments and ^1H NMR studies, we propose that the anion binding interaction between thiourea and chloride counterion plays an important role in the catalytic system. Deuteration experiments suggested that the hydrogenation proceeded through a pathway consistent with the imine. Further research on the mechanism of catalysis and other applications is currently under way, as is the use of the HTS methodology.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. For reviews: a) Nugent, TC. *Chiral Amine Synthesis: Methods, Developments and Applications*. Wiley-VCH; Weinheim: 2010. b) Zhang, W., Zhang, X. *Comprehensive Chirality*. Carreira, EM., Yamamoto, H., editors. Elsevier; Amsterdam: 2012. p. 301-317. c) Xie JH, Zhu SF, Zhou QL. *Chem Rev*. 2010; 111:1713–1760. [PubMed: 21166392] d) Nugent TC, El-Shazly M. *Adv Synth Catal*.

- 2010; 352:753–819.e) Yu Z, Jin W, Jiang Q. *Angew Chem.* 2012; 124:6164. *Angew Chem Int Ed.* 2012; 51:6060–6072.
2. For examples of asymmetric reductive amination: a) Blaser HU, Buser HP, Jalett HP, Pugin B, Spindler F. *Synlett.* 1999:867–868. b) Chi Y, Zhou YG, Zhang X. *J Org Chem.* 2003; 68:4120–4122. [PubMed: 12737606] c) Kadyrov R, Riermeier TH. *Angew Chem.* 2003; 115:5630. *Angew Chem Int Ed.* 2003; 42:5472–5474. d) Williams GD, Pike RA, Wade CE, Wills M. *Org Lett.* 2003; 5:4227–4230. [PubMed: 14572291] e) Steinhuebel D, Sun Y, Matsumura K, Sayo N, Saito T. *J Am Chem Soc.* 2009; 131:11316–11317. [PubMed: 19637921] f) Li C, Villa-Marcos B, Xiao J. *J Am Chem Soc.* 2009; 131:6967–6969. [PubMed: 19402701] g) Mattei P, Moine Gr, Püntener K, Schmid R. *Org Process Res Dev.* 2011; 15:353–359. h) Strotman NA, Baxter CA, Brands KMJ, Cleator E, Krska SW, Reamer RA, Wallace DJ, Wright TJ. *J Am Chem Soc.* 2011; 133:8362–837. [PubMed: 21528938] i) Chang M, Liu S, Huang K, Zhang X. *Org Lett.* 2013; 15:4354–4357. [PubMed: 23937659] j) Talwar D, Salguero NP, Robertson CM, Xiao J. *Chem Eur J.* 2014; 20:245–252. [PubMed: 24516890]
3. For examples: a) Hsiao Y, Rivera NR, Rosner T, Krska SW, Njolito E, Wang F, Sun Y, Armstrong JD, Grabowski EJJ, Tillyer RD, Spindler F, Malan C. *J Am Chem Soc.* 2004; 126:9918–9919. [PubMed: 15303855] b) Clausen AM, Dziadul B, Cappuccio KL, Kaba M, Starbuck C, Hsiao Y, Dowling TM. *Org Process Res Dev.* 2006; 10:723–726. c) Hansen KB, Hsiao Y, Xu F, Rivera N, Clausen A, Kubryk M, Krska S, Rosner T, Simmons B, Balsells J, Ikemoto N, Sun Y, Spindler F, Malan C, Grabowski EJJ, Armstrong JD. *J Am Chem Soc.* 2009; 131:8798–8804. [PubMed: 19507853] d) Hou G, Li W, Ma M, Zhang X, Zhang X. *J Am Chem Soc.* 2010; 132:12844–12846. [PubMed: 20795623] e) Birch M, Challenger S, Crochard JP, Fradet D, Jackman H, Luan A, Madigan E, Mathew JS, McDowall N, Meldrum K, Gordon CM, Peach P, Yeo S. *Org Process Res Dev.* 2011; 15:1358–1364. f) Matsumura K, Zhang X, Hori K, Murayama T, Ohmiya T, Shimizu H, Saito T, Sayo N. *Org Process Res Dev.* 2011; 15:1130–1137.
4. For examples of asymmetric transfer hydrogenation: a) Gosselin F, O'Shea PD, Roy S, Reamer RA, Chen C-y, Volante RP. *Org Lett.* 2004; 7:355–358. b) Nguyen TB, Bousserouel H, Wang Q, Guéritte Fo. *Org Lett.* 2010; 12:4705–4707. [PubMed: 20857955] c) Nguyen TB, Wang Q, Guéritte F. *Chem Eur J.* 2011; 17:9576–9580. [PubMed: 21805514]
5. a) Hou G, Gosselin F, Li W, McWilliams JC, Sun Y, Weisel M, O'Shea PD, Chen C-y, Davies IW, Zhang X. *J Am Chem Soc.* 2009; 131:9882–9883. [PubMed: 19569686] b) Hou G, Tao R, Sun Y, Zhang X, Gosselin F. *J Am Chem Soc.* 2010; 132:2124–2125. [PubMed: 20104899]
6. Pyrrolidinium salts: a) Magee MP, Norton JR. *J Am Chem Soc.* 2001; 123:1778–1779. [PubMed: 11456787] b) Guan H, Iimura M, Magee MP, Norton JR, Janak KE. *Organometallics.* 2003; 22:4084–4089. c) Guan H, Iimura M, Magee MP, Norton JR, Zhu G. *J Am Chem Soc.* 2005; 127:7805–7814. [PubMed: 15913370] Quinolinium salts: d) Tadaoka H, Cartigny D, Nagano T, Gosavi T, Ayad T, Genêt JP, Ohshima T, Ratovelomanana-Vidal V, Mashima K. *Chem Eur J.* 2009; 15:9990–9994. [PubMed: 19711392] Isoquinolinium salts: e) Iimuro A, Yamaji K, Kandula S, Nagano T, Kita Y, Mashima K. *Angew Chem.* 2013; 125:2100. *Angew Chem Int Ed.* 2013; 52:2046–2050.
7. a) Zhou S, Fleischer S, Junge K, Beller M. *Angew Chem.* 2011; 123:5226–5230. *Angew Chem Int Ed.* 2011; 50:5120–5124. b) Tang W, Johnston S, Iggo JA, Berry NG, Phelan M, Lian L, Bacsa J, Xiao J. *Angew Chem.* 2013; 125:1712–1716. *Angew Chem Int Ed.* 2013; 52:1668–1672.
8. For reviews: a) Pihko, PM. *Hydrogen Bonding in Organic Synthesis.* Wiley-VCH; Weinheim, Germany: 2009. b) Zhang Z, Schreiner PR. *Chem Soc Rev.* 2009; 38:1187–1198. [PubMed: 19421588] c) Knowles RR, Jacobsen EN. *Proc Natl Acad Sci U S A.* 2010; 107:20678–20685. [PubMed: 20956302]
9. For reviews: a) Phipps RJ, Hamilton GL, Toste FD. *Nat Chem.* 2012; 4:603–614. [PubMed: 22824891] b) Brak K, Jacobsen EN. *Angew Chem.* 2013; 125:558–588. *Angew Chem Int Ed.* 2013; 52:534–561. c) Mahlau M, List B. *Angew Chem.* 2013; 125:540–556. *Angew Chem Int Ed.* 2013; 52:518–533.
10. a) Taylor MS, Jacobsen EN. *J Am Chem Soc.* 2004; 126:10558–10559. [PubMed: 15327311] b) Taylor MS, Tokunaga N, Jacobsen EN. *Angew Chem.* 2005; 117:6858. *Angew Chem Int Ed.* 2005; 44:6700–6704. c) Raheem IT, Thiara PS, Peterson EA, Jacobsen EN. *J Am Chem Soc.* 2007; 129:13404–13405. [PubMed: 17941641] d) Zuend SJ, Jacobsen EN. *J Am Chem Soc.* 2009; 131:15358–15374. [PubMed: 19778044] e) Knowles RR, Lin S, Jacobsen EN. *J Am Chem Soc.*

- 2010; 132:5030–5032. [PubMed: 20369901] f) Xu H, Zuend SJ, Woll MG, Tao Y, Jacobsen EN. Science. 2010; 327:986–990. [PubMed: 20167783] g) Birrell JA, Desrosiers JN, Jacobsen EN. J Am Chem Soc. 2011; 133:13872–13875. [PubMed: 21800916] h) Burns NZ, Witten MR, Jacobsen EN. J Am Chem Soc. 2011; 133:14578–14581. [PubMed: 21848300] i) Lin S, Jacobsen EN. Nat Chem. 2012; 4:817–824. [PubMed: 23000995] j) Lalonde MP, McGowan MA, Rajapaksa NS, Jacobsen EN. J Am Chem Soc. 2013; 135:1891–1894. [PubMed: 23321009] k) Bergonzini G, Schindler CS, Wallentin CJ, Jacobsen EN, Stephenson CR. Chem Sci. 2014; 5:112–116.
11. a) De CK, Klauber EG, Seidel D. J Am Chem Soc. 2009; 131:17060–17061. [PubMed: 19929016] b) Klauber EG, De CK, Shah TK, Seidel D. J Am Chem Soc. 2010; 132:13624–13626. [PubMed: 20843041] c) De CK, Seidel D. J Am Chem Soc. 2011; 133:14538–14541. [PubMed: 21863902] d) Min C, Mittal N, Sun DX, Seidel D. Angew Chem. 2013; 125:14334–14338. Angew Chem Int Ed. 2013; 52:14084–14088.
12. a) Lee YS, Alam MM, Keri RS. Chem Asian J. 2013; 8:2906–2919. [PubMed: 24030776] b) Schafer AG, Wieting JM, Fisher TJ, Mattson AE. Angew Chem. 2013; 125:11531–11534. Angew Chem Int Ed. 2013; 52:11321–11324.
13. Zhao Q, Li S, Huang K, Wang R, Zhang X. Org Lett. 2013; 15:4014–4017. [PubMed: 23883313]
14. For more details, see supplementary information.
15. Phenyl(p-tolyl)methaniminium chloride and (2-Chlorophenyl)(phenyl)methaniminium chloride were used while no desired product was obtained under the optimized conditions.
16. Lippert KM, Hof K, Gerbig D, Ley D, Hausmann H, Guenther S, Schreiner PR. Eur J Org Chem. 2012; 2012:5919–5927.
17. Dagna JM, Pescitelli G, Tran L, Lynch VM, Anslyn EV, Di Bari L. J Am Chem Soc. 2012; 134:4398–4407. [PubMed: 22272943]

Figure 1.
Related drugs (candidates) containing chiral amines.

Figure 2.
Extension of our Rh/Bisphosphine-Thiourea catalytic system.

Figure 3.

a) ^1H NMR spectra of **L6** with TBAC; b) ^1H NMR spectra of **L7** with TBAC. The NH were marked.

Scheme 1.

[a] **1a** (0.1 mmol) and a Rh/L ratio of 1/1.1 in 1.0 mL solvent. [b] ee and conversion was determined by chiral GC of the corresponding acetamides.

Scheme 2.

[a] Reaction conditions: **1** (0.2 mmol) and a Rh/L ratio of 1/1.1 in 2.0 mL solvent. [b] Isolated yield. [c] ee was determined by chiral GC of the corresponding acetamides. [d] 45 °C, 50 atm H₂. [e] 25 °C, 5 atm H₂; ee was determined by chiral GC of the free amines.

Scheme 3.
Deuteration experiment.

Table 1

Ligands study and control experiments. ^[a]

Entry	Ligand	Conv. ^[b] [%]	ee ^[b] [%]
1	L1	2	55
2	L2	22	66
3	L3	6	11
4	L4	72	87
5	L5	76	90
6	L6	99	94
7	L7	26	38
8	L8	2	11
9	L9	9	84
10 ^[c]	L8	5	8
11 ^[d]	L1	9	57

^[a] Reaction conditions: **1a** (0.1 mmol) and a Rh/L/**1a** ratio of 1/1.1/100 in 1.0 mL solvent.^[b] Determined by chiral GC of the corresponding acetamides.^[c] Rh/L/**1a**/Ph₃P = 1/1.1/100/2.2.^[d] Rh/L/**1a**/thiourea = 1/1.1/100/1.1.

Table 2Substrates study and control experiments. ^[a]

Entry	1	Additive	Conv. ^[b] [%]	ee ^[b] [%]
1	1p	—	20	53
2	1p	TBAC	86	94
3	1p	LiCl	71	93
4	1a	—	99	94
5	1a	TBAB	77	90
6	1a	TBAI	32	89

^[a] **1a** (0.1 mmol) and a Rh/L/**1a**/Additive ratio of 1/1.1/100/100 in 1.0 mL solvent.

^[b] Determined by chiral GC of the corresponding acetamides.